Key topics:

• Cutting-Edge Therapies: Advances in TPD, ADCs, therapeutic peptides, and theranostic radiopharmaceuticals.
• Next-Generation Models: Organoid platforms, AI and mechanism-based modeling (PBPK/QSP), and non-human primate models.
• Nonclinical Safety: Risk assessment for drug-induced liver injury, advanced biotherapeutic evaluation in non-human primates, and iPSC-derived organoid cardiotoxicity models.

Meet our team on site:

• Mr. Haiming Tang brings over 30 years of preclinical safety and research experience from Roche, Novartis, Relay Therapeutics, and Degron Therapeutics, with expertise in toxicology, safety pharmacology, and cardiovascular pharmacology.
• Dr. Yongmei Xu, Ph.D. from Shanghai Organic Chemistry Institute of China Academy of Sciences and postdoctoral fellow at Stockholm University, has over 20 years of experience in drug discovery R&D. She has led numerous innovative pharmaceutical R&D projects at Medicilon.

What we offer

As a full-service preclinical CRO, Medicilon accelerates your drug R&D path from Idea to IND with specialized solutions aligned with this year’s symposium focus:

For Cutting-Edge Therapies (TPD, ADC, Peptides, etc.)

• Dedicated platforms for new modalities: ADCs, AOCs, PROTACs, mRNA vaccines, oligonucleotides, CGTs, and more
• In vivo efficacy models for novel mechanisms: TPD, ADC payload delivery, peptides, and more

For Next-Generation Models (Organoid, AI/PBPK/QSP, NHP)

• Organoid-based platforms for nonclinical evaluation
• AI-driven drug discovery solutions and mechanism-based modeling (PBPK/QSP) for global regulatory submissions

For Nonclinical Safety

• Risk assessment strategies for drug-induced liver injury (DILI) mediated by reactive metabolites
• GLP-compliant safety & toxicology studies for cell and gene therapies in NHPs

Our core capabilities across the entire R&D path:

• Drug discovery – target validation, assay development, translational models
• Over 1,000 in vivo efficacy models covering both oncology (CDX, PDX, orthotopic, humanized) and non-oncology disease areas (inflammation & immunology, metabolic, CNS, cardiovascular, ophthalmic, etc.)
• IND-enabling studies: pharmacokinetics, pharmacodynamics, safety & toxicology (GLP-compliant with FDA, NMPA, OECD…)
• Pharmaceutical development: API & formulation process development, quality and stability studies

With 650⁺ IND approvals supported worldwide and flexible collaboration models (FTE/FFS), we are ready to accelerate your precision medicine program from discovery to clinic.

Visit Medicilon at Booth #21 to explore how we can support your drug R&D journey aligned with KSNS 2026.